FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3094037321> ?p ?o ?g. }

• W3094037321 endingPage "e94" @default.
• W3094037321 startingPage "e93" @default.
• W3094037321 abstract "PD-1 checkpoint blockade (CPB) has shown promising response rates in patients with metastatic non-small cell lung cancer (NSCLC), while anti-CTLA-4 has failed to demonstrate efficacy. We previously reported in chemo-resistant patients that treatment with radiotherapy (RT) plus CTLA-4 resulted in 18% objective response rate (ORR). Responses were associated with increase in Type I Interferon and early dynamic changes of T-cell receptor repertoire measured in peripheral blood. In one responder, the expansion and persistence of tumor T cell clonotypes enabled the identification of neoantigen-specific CD8 T cells. We hypothesized that RT in combination with dual CPB may further improve responses compared to patients historically treated with single or dual agent CPB or RT plus single agent CPB. We present the preliminary results of a prospective phase I-II study designed to test the hypothesis that local RT with dual checkpoint blockade is safe and can achieve an ORR of >50%. Eligible patients include histologically proven metastatic NSCLC, older than 18, with at least two measurable disease sites, adequate organ function, and ECOG PS 0-1. RT, 30 Gy in 5 fractions, directed to one lesion, is given within 24 hours of CTLA-4 blockade, using ipilimumab (3 mg/kg). On day 22, patients receive dual ICB, consisting of ipilimumab (1 mg/kg) and PD-1 blockade by nivolumab (360 mg). Ipilimumab is given every 6 weeks and nivolumab every 2-3 weeks until progression. Responses are assessed by RECIST criteria at day 70 ± 7, based on assessment of measurable disease outside of the RT field. Toxicities are reported per CTCAE version 5. The trial is designed with Simon’s two stage optimal design, with >5/15 patients required to respond in stage 1 to proceed to the stage 2 and accrue an additional 29 patients. With a 90% power to detect a difference between the null hypothesis (>30% ORR) versus the alternative (>50%ORR), the trial will have a type 1 error probability of 10%. A total of 9 patients were enrolled to date with 7 patients being evaluable for treatment response. Immunohistochemistry for PDL-1, performed using the FDA approved protocol for SP263 antibody on a Ventana Benchmark Ultra automatic stainer and scored on tumor cells, was <50%, >50% and unknown in 5, 1 and 1 patients, respectively. There was 1 complete response, 1 partial response, 3 with stable disease, 2 with disease progression. No treatment related toxicities of grade ≥3 occurred. The trial continues enrollment. Updated results and immunological correlates will be presented at ASTRO." @default.
• W3094037321 created "2020-10-29" @default.
• W3094037321 creator A5010278889 @default.
• W3094037321 creator A5023774862 @default.
• W3094037321 creator A5037701284 @default.
• W3094037321 creator A5048709555 @default.
• W3094037321 creator A5052554629 @default.
• W3094037321 creator A5074015095 @default.
• W3094037321 creator A5075739031 @default.
• W3094037321 creator A5084238548 @default.
• W3094037321 creator A5091464373 @default.
• W3094037321 date "2020-11-01" @default.
• W3094037321 modified "2023-10-14" @default.
• W3094037321 title "Radiation and Immune Checkpoints Blockade in Metastatic NSCLC (NCT03168464)" @default.
• W3094037321 doi "https://doi.org/10.1016/j.ijrobp.2020.07.1197" @default.
• W3094037321 hasPublicationYear "2020" @default.
• W3094037321 type Work @default.
• W3094037321 sameAs 3094037321 @default.
• W3094037321 citedByCount "0" @default.
• W3094037321 crossrefType "journal-article" @default.
• W3094037321 hasAuthorship W3094037321A5010278889 @default.
• W3094037321 hasAuthorship W3094037321A5023774862 @default.
• W3094037321 hasAuthorship W3094037321A5037701284 @default.
• W3094037321 hasAuthorship W3094037321A5048709555 @default.
• W3094037321 hasAuthorship W3094037321A5052554629 @default.
• W3094037321 hasAuthorship W3094037321A5074015095 @default.
• W3094037321 hasAuthorship W3094037321A5075739031 @default.
• W3094037321 hasAuthorship W3094037321A5084238548 @default.
• W3094037321 hasAuthorship W3094037321A5091464373 @default.
• W3094037321 hasBestOaLocation W30940373211 @default.
• W3094037321 hasConcept C126322002 @default.
• W3094037321 hasConcept C143998085 @default.
• W3094037321 hasConcept C170493617 @default.
• W3094037321 hasConcept C203014093 @default.
• W3094037321 hasConcept C2778468042 @default.
• W3094037321 hasConcept C502942594 @default.
• W3094037321 hasConcept C71924100 @default.
• W3094037321 hasConcept C8891405 @default.
• W3094037321 hasConceptScore W3094037321C126322002 @default.
• W3094037321 hasConceptScore W3094037321C143998085 @default.
• W3094037321 hasConceptScore W3094037321C170493617 @default.
• W3094037321 hasConceptScore W3094037321C203014093 @default.
• W3094037321 hasConceptScore W3094037321C2778468042 @default.
• W3094037321 hasConceptScore W3094037321C502942594 @default.
• W3094037321 hasConceptScore W3094037321C71924100 @default.
• W3094037321 hasConceptScore W3094037321C8891405 @default.
• W3094037321 hasIssue "3" @default.
• W3094037321 hasLocation W30940373211 @default.
• W3094037321 hasOpenAccess W3094037321 @default.
• W3094037321 hasPrimaryLocation W30940373211 @default.
• W3094037321 hasRelatedWork W12589998 @default.
• W3094037321 hasRelatedWork W14289313 @default.
• W3094037321 hasRelatedWork W14576825 @default.
• W3094037321 hasRelatedWork W158596 @default.
• W3094037321 hasRelatedWork W16736519 @default.
• W3094037321 hasRelatedWork W1912601 @default.
• W3094037321 hasRelatedWork W19244877 @default.
• W3094037321 hasRelatedWork W20305632 @default.
• W3094037321 hasRelatedWork W21144364 @default.
• W3094037321 hasRelatedWork W17292841 @default.
• W3094037321 hasVolume "108" @default.
• W3094037321 isParatext "false" @default.
• W3094037321 isRetracted "false" @default.
• W3094037321 magId "3094037321" @default.
• W3094037321 workType "article" @default.